Henlius Swallows Bitter Pill in Watered-Down Licensing Deal 对外授权订单缩水 复宏汉霖“出海”遇阻？
The innovative drug company will receive less benefits from an existing licensing deal after revisions to reflect high R&D costs 这家创新药企业的一项授权合作的最高收入将会减少，为股价带来负面影响。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.